Sino-Singapore Health: China's renal cancer immunotherapy achieves "zero breakthrough" Tuoyi® + axitinib benefits advanced patients. Kidney cancer is the third most common malignant tumor of the urinary system in the world.
It accounts for 80% to 90% of all kidney cancer cases. Previously, no immunotherapy for kidney cancer had been approved in China. The approval of toripalimab combined with axit inib therapy fills the gaps in first-line immunotherapy.